Last updated on March 2018

A clinical trial to evaluate treatments using Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05), Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321) for patients with Macular Edema

Brief description of study

Intravitreal aflibercept has been approved for the treatment of visual impairments due to diabetic macular oedema (DMO) in Europe and the US in August 2014 and July 2014 respectively.

The main objectives of this observational cohort field study are to evaluate effectiveness of intravitreal aflibercept and to describe follow-up as well as treatment patterns in anti vascular endothelial growth factor (anti-VEGF) treatment nave patients with DMO in routine clinical practice in the United Kingdom.

Clinical Study Identifier: NCT02850263

Contact Investigators or Research Sites near you

Start Over

Bayer Clinical Trials Contact

Multiple Locations, United Kingdom
  Connect »